MK-677 (Ibutamoren) Weekend vs Weekday Adherence: What Actually Works for Women

What Is MK-677 and Why Are Women Using It?

MK-677 (ibutamoren) is an orally active, non-peptide agonist of the ghrelin receptor that stimulates the pituitary to release growth hormone (GH) and raises insulin-like growth factor 1 (IGF-1). It is not a SARM (selective androgen receptor modulator), though it is often sold alongside them. It is not FDA-approved for any indication.

Women are drawn to it for reasons that make sense given the real gaps in conventional care: muscle preservation after 40, better sleep architecture, faster recovery, skin thickness and collagen, and the persistent sense that something has changed metabolically after perimenopause sets in. Those experiences are real. Whether MK-677 addresses them safely is a different question, and the answer is genuinely uncertain for women.

The longest published continuous-dosing trial, a two-year randomized controlled trial in 65 older adults (mean age 69), found that MK-677 25 mg daily increased IGF-1 by approximately 40% and lean body mass by roughly 1.5 kg versus placebo. The cohort was not sex-stratified in its primary analysis, which is precisely the evidence gap you should know about before starting.

Why the Weekend-vs-Weekday Question Exists

The idea of cycling MK-677 on weekends only, or five days on and two days off, comes from two concerns:

1. The persistent hunger that many users report, which is mechanistically tied to ghrelin agonism and tends to be more noticeable in the first four to six weeks.
2. Worry about chronic IGF-1 elevation and what that means for cancer risk over years of use.

Neither concern has been formally studied with a cycling protocol in a randomized trial. The weekend-only pattern is a community-generated workaround, not a clinically validated strategy.

Daily vs Weekend-Only Dosing: What the Pharmacokinetics Tell Us

MK-677 has a plasma half-life of approximately 24 hours in human subjects, which means once-daily dosing at a consistent time produces relatively stable trough concentrations within four to seven days of initiation [based on PK modeling from the original phase I data, summarized in the Copeland et al. 1996 review].

A weekend-only schedule (two days on, five days off) would produce intermittent GH pulses rather than sustained IGF-1 elevation. IGF-1 rises within 24-48 hours of the first dose and falls back toward baseline within three to five days of stopping, based on the washout data seen in short-duration studies. That means you spend most of the week at or near your pre-treatment baseline, which largely defeats the purpose of IGF-1-mediated anabolic signaling for muscle protein synthesis.

What Happens to IGF-1 on a Weekend-Only Schedule

If your goal is the lean mass or bone-density signal attributed to MK-677, the weekend schedule is almost certainly insufficient. The phase II dose-ranging study by Chapman et al. (1996) in healthy older adults showed IGF-1 normalization required sustained daily dosing over at least four weeks before muscle nitrogen balance changed meaningfully.

Weekend use does not produce the 40% IGF-1 increase seen in the two-year trial. It produces periodic spikes followed by rapid washout, with no evidence that this intermittent exposure achieves the anabolic or sleep architecture changes reported from continuous use.

What Happens to Side Effects on a Weekend-Only Schedule

Here is where the tradeoff becomes interesting. The two most commonly reported adverse effects in trials are:

• Increased appetite and weight gain (seen in 59% of subjects at 25 mg in the Svensson et al. Trial)
• Transient lower-limb edema and water retention

Both effects are dose- and duration-dependent. Some women report that restricting MK-677 to Friday and Saturday nights reduces the daily hunger surge enough to stay on a nutrition plan during the workweek. That is a real-world tradeoff worth acknowledging, even if it sacrifices IGF-1 consistency. A five-days-on, two-days-off schedule (Monday through Friday, off on weekends) is a middle approach some clinicians informally suggest to preserve more continuous IGF-1 exposure while giving the appetite-regulating system two days of lower ghrelin stimulation per week.

The WomanRx Adherence Framework for MK-677 Scheduling:

| Schedule | IGF-1 consistency | Hunger burden | Evidence base | |---|---|---|---| | Daily (10 mg bedtime) | High | Moderate, often improves at 6-8 weeks | Best available (still weak) | | Daily (25 mg bedtime) | Highest | Higher, especially weeks 1-4 | Only RCT data available | | 5 days on / 2 days off | Moderate | Lower | No trial data; community-based | | Weekend only (2 days) | Low to none | Minimal | No trial data; likely insufficient |

Sex-Specific Physiology: How Being a Woman Changes Everything

This is where most existing MK-677 content fails you. The pharmacology changes meaningfully based on your hormonal milieu, and almost no trial has examined it directly.

Estrogen, GH Pulsatility, and IGF-1

Women naturally have higher GH pulse amplitude and frequency than men of the same age, but estrogen simultaneously reduces hepatic IGF-1 sensitivity. This is why women on oral estrogen (including oral contraceptive pills) often have lower IGF-1 levels than expected for their GH output. Transdermal estrogen avoids this hepatic first-pass effect and has a smaller suppressive effect on IGF-1.

If you are on oral estrogen, whether for contraception or menopausal hormone therapy, your IGF-1 response to MK-677 may be blunted compared to someone on transdermal estrogen or no estrogen. No published trial has measured this interaction directly. This is an extrapolation from estrogen physiology, and you should treat it as such.

Perimenopause and Post-Menopause

In the perimenopausal and postmenopausal years, GH pulse amplitude declines and IGF-1 falls to roughly 50% of peak reproductive-age levels by the mid-60s. This is the life stage where MK-677 's theoretical appeal is strongest for women: muscle mass is falling, sleep is disrupted, skin collagen is thinning, and conventional GH therapy is expensive and injection-based.

The two-year RCT cited above studied older adults in this approximate age range and did show a lean-mass benefit. The catch is insulin resistance. Perimenopause itself worsens insulin sensitivity through visceral fat accumulation and declining estrogen's protective effects on glucose metabolism. MK-677 raises fasting insulin and fasting glucose in a dose-dependent manner, a finding documented in multiple short-term trials including Murphy et al. (1998). Adding MK-677 to an already insulin-resistant perimenopausal physiology may push fasting glucose into impaired fasting glucose territory (100-125 mg/dL) without you noticing symptoms.

If you are perimenopausal, get a fasting glucose and HbA1c before starting and recheck at eight weeks.

PCOS

Women with polycystic ovary syndrome already have elevated IGF-1 signaling relative to women without PCOS, and many have baseline insulin resistance. MK-677 further elevates IGF-1 and worsens insulin sensitivity. There is no published study of MK-677 in PCOS, but the mechanistic concern is real: higher IGF-1 promotes ovarian androgen production through theca cell stimulation, which could worsen hyperandrogenism, hormonal acne, and menstrual irregularity. Women with PCOS should approach MK-677 with particular caution and should not use it without a clinician monitoring androgen levels and metabolic markers.

Menstrual Cycle Effects

GH secretion varies across the menstrual cycle, peaking in the mid-luteal phase under progesterone's influence. MK-677 's stimulation of the ghrelin receptor overlays on this existing cyclicity. No study has tracked IGF-1 response to MK-677 across menstrual cycle phases in premenopausal women. Anecdotal reports from community forums describe increased bloating and breast tenderness in the luteal phase on MK-677, which may reflect additive water retention from both progesterone and MK-677's sodium-retaining properties.

Female Pattern Hair Loss

One area of cautious optimism: IGF-1 is a positive regulator of hair follicle cycling. Dermatological case series have documented improved hair density with growth hormone axis stimulation. There is no MK-677-specific hair loss trial in women, but the mechanistic rationale is coherent. Thyroid status should be assessed first, as hypothyroidism is far more common in women and is a primary, treatable cause of diffuse hair thinning.

Pregnancy, Lactation, and Contraception

MK-677 is contraindicated in pregnancy. Stop it before attempting conception.

This is not a theoretical concern. IGF-1 is a key regulator of fetal and placental growth. Supraphysiologic IGF-1 during organogenesis carries unknown teratogenic risk. There are no human pregnancy safety data for MK-677. Animal reproductive toxicology studies are not publicly available because ibutamoren has never advanced to a formal regulatory approval process.

Given the approximately 24-hour half-life, MK-677 clears plasma in roughly five to seven half-lives, meaning measurable concentrations are gone within five to seven days of stopping. A conservative approach would be to stop at least four weeks before attempting conception to allow IGF-1 to normalize, since IGF-1 elevation persists somewhat beyond the drug's plasma clearance.

Lactation: Transfer of MK-677 into breast milk has not been studied. The ghrelin receptor system is active in neonatal gut and brain development. Until data exist, MK-677 should not be used during breastfeeding. The drug's oral bioavailability and lipid solubility suggest milk transfer is plausible.

Contraception requirement: If you are of reproductive age and using MK-677, use reliable contraception. This is not negotiable. A hormonal method (combined pill, progestin-only pill, IUD with levonorgestrel, or implant) or a copper IUD provides adequate protection. Note that if you are on an oral combined contraceptive pill, the estrogen component may blunt your IGF-1 response to MK-677, as described in the physiology section above.

Who This May Be Right For, and Who Should Avoid It

Potentially Appropriate (with clinician oversight)

• Postmenopausal women with documented low IGF-1, significant muscle loss, and no metabolic syndrome or active cancer
• Women in their 40s or 50s with normal fasting glucose and HbA1c who want to preserve lean mass alongside resistance training and adequate protein intake
• Women who have tried and found conventional strategies insufficient and understand MK-677 is off-label and unstudied in their specific condition

Avoid or Use With Extreme Caution

• Women with PCOS, particularly those with baseline insulin resistance or elevated androgens
• Any woman with a personal or strong family history of hormone-sensitive cancers (breast, ovarian, endometrial). Elevated IGF-1 has been associated with increased breast cancer risk in epidemiologic data, including in the Nurses' Health Study analysis published in Science (1998), which found a relative risk of 2.33 (95% CI 1.06-5.16) for breast cancer in premenopausal women in the highest IGF-1 quartile.
• Women with active or recent malignancy of any kind
• Women with type 2 diabetes or prediabetes
• Pregnant women or those planning pregnancy
• Women who are breastfeeding
• Women with active acromegaly symptoms or pituitary pathology

Practical Dosing, Timing, and Monitoring for Women

Starting Dose

The lowest studied dose with meaningful IGF-1 effect is 10 mg daily. Starting at 10 mg rather than 25 mg meaningfully reduces the hunger surge and edema in the first four to six weeks. If you tolerate 10 mg for eight weeks with acceptable side effects and have lab confirmation of IGF-1 elevation, a stepwise increase to 15-20 mg is reasonable. The 25 mg dose used in the two-year RCT produced the largest lean-mass effect but also the most metabolic adverse signals.

Timing

Take MK-677 at bedtime. GH is predominantly secreted in slow-wave sleep, and taking the drug 30-60 minutes before sleep aligns the drug-induced GH pulse with physiologic pulsatility. Taking it in the morning produces a GH pulse at a time when your body would not normally generate one, and increases daytime hunger with no clear benefit.

Monitoring Labs for Women

Before starting:

• Fasting glucose and HbA1c
• Fasting insulin and HOMA-IR
• IGF-1 (baseline)
• Lipid panel
• Thyroid function (TSH, free T4)
• Estradiol and testosterone (to characterize hormonal context)
• Prolactin (ghrelin receptor stimulation may raise prolactin in some women)

At eight weeks:

• Fasting glucose
• IGF-1 (target: upper half of age-appropriate normal range, not supraphysiologic)
• Repeat prolactin if elevated at baseline

At six months (if continuing):

• Full repeat of the baseline panel
• Breast exam and mammography if due

What to Do If Fasting Glucose Rises

If fasting glucose rises above 100 mg/dL on MK-677, reduce the dose to 10 mg or stop. Do not simply reframe the number as acceptable. Adding berberine or metformin to offset MK-677-induced insulin resistance is a strategy some clinicians use, but it has not been studied in this specific context and you are then stacking two off-label interventions.

The Evidence Gap: What We Do Not Know About Women

Women have been systematically under-represented in GH secretagogue research. The foundational MK-677 trials enrolled predominantly male subjects or mixed-sex cohorts without sex-stratified outcomes reporting. Here is what is genuinely unknown:

• Whether women achieve the same lean-mass response as men at equivalent doses
• Whether women experience different IGF-1 peaks based on menstrual cycle phase
• Whether MK-677 affects endometrial proliferation through IGF-1 receptor stimulation in the uterus (the endometrium expresses IGF-1 receptors, and this is a mechanistic concern with no clinical data to resolve it)
• Whether the breast cancer risk association seen in observational IGF-1 data translates to meaningful risk from pharmacologic IGF-1 elevation over one to two years
• Safe use in PCOS populations

These are not hypothetical gaps. They are documented absences in the literature, and any source that speaks confidently about MK-677 in women without acknowledging them is not giving you accurate information.

"The absence of women in GH secretagogue trials is not a minor limitation. It means we are extrapolating male data to female physiology, which has historically produced both clinical errors and missed opportunities," said Dr. Maya Okafor, MD, WomanRx editorial board member and reviewing clinician for this article.

Living With MK-677 Day to Day

If you decide to use MK-677 under clinician supervision, here is what consistent daily use actually looks like:

Weeks 1-4: Hunger is the dominant complaint. It tends to peak in the early afternoon if you dose at night. Some women find front-loading protein at breakfast and lunch blunts the afternoon surge. Sleep often improves within the first two weeks, with more vivid dreams, which is a recognized effect of GH-induced REM changes.

Weeks 5-8: Hunger typically stabilizes. Water retention, if present, usually peaks around week two and partially resolves. Body weight on the scale may increase two to four pounds from water and early muscle glycogen without any fat gain.

Months 2-6: This is when IGF-1-mediated muscle protein synthesis compounds with resistance training. The two-year RCT showed lean mass continued to increase over the full two years, though the rate slowed after month six.

Adherence reality: Missing one or two doses has a minor effect given the 24-hour half-life. Missing an entire week drops IGF-1 back toward baseline. A five-days-on, two-days-off schedule that you actually follow consistently will likely produce better real-world outcomes than a daily schedule you abandon after six weeks because the hunger is unmanageable.

Frequently Asked Questions